After positive results in phase 3 trials, a GSK experimental therapy could be the first ultra-long-acting biologic approved for severe asthma. The drug candidate, depemokimab, was measured in severe ...

A landmark study has shown that severe asthma can be controlled using biologic therapies, without the addition of regular high-dose inhaled steroids which can have significant side effects. A landmark ...

A new study has found that using biologic therapy to reduce lung inflammation enabled 92% of people with severe asthma to reduce their dose of daily inhaled steroid without exacerbating their symptoms ...

Mepolizumab significantly reduces exacerbations in patients with asthma and concurrent chronic obstructive pulmonary disease (COPD), with a 55% reduction in COPD exacerbations post initiation. A ...

Adding a novel, ultra-long-acting biologic to standard care for patients with severe asthma and type 2 inflammation significantly reduced exacerbations, a pair of phase IIIA trials showed. Across the ...

A phase 4 study found severe asthma can be controlled using biologic therapies, without the addition of high-dose inhaled steroids. Among a cohort of patients with severe asthma using the biologic ...

Rochester, Minn.-based Mayo Clinic researchers have developed AI tools to help identify young children at highest risk for severe asthma and acute respiratory infections. The tools use machine ...